Search
Now showing items 71-77 of 77
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
(NATURE PUBLISHING GROUP, 2005-02-14)
The British mesothelioma register contains all deaths from 1968 to 2001 where mesothelioma was mentioned on the death certificate. These data were used to predict the future burden of mesothelioma mortality in Great Britain. ...
Synthesis of trisubstituted pyrimidines by regioselective S<sub>N</sub>Ar and Suzuki reactions of polyhalopyrimidines
(GEORG THIEME VERLAG KG, 2006-04-04)
An efficient, regioselective approach to the synthesis of trisubstituted pyrimidines was developed. Sequential functionalization of com. available polyhalopyrimidines provided the target compds. in moderate to good overall ...
Factors associated with emotional and behavioural problems among school age children of breast cancer patients
(2006-01-16)
To identify factors linked with emotional and behavioural problems in school age (6- to 17-year-old) children of women with breast cancer. Reports of children’s emotional and behavioural problems were obtained from patient ...
Body fatness and physical activity at young ages and the risk of breast cancer in premenopausal women
(NATURE PUBLISHING GROUP, 2005-10-03)
We examined the relationship between body fatness, sports participation and breast cancer risk in 1560 premenopausal cases and 1548 controls, from three related population-based case - control studies in the UK. Half of ...
HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial
(NATURE PUBLISHING GROUP, 2006-07-03)
To evaluate the effectiveness of human papillomavirus (HPV) testing in primary cervical screening. This was a cross-sectional study from the recruitment phase of a prospective randomised trial. Women were screened for HPV ...
Randomised controlled trial of mammographic screening in women from age 40: results of screening in the first 10 years
(NATURE PUBLISHING GROUP, 2005-03-14)
Debate continues over the effectiveness of screening by mammography in women below age 50. We report here on results of screening in the first 10 years of a randomised trial to study the effect on breast cancer mortality ...
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
(NATURE PUBLISHING GROUP, 2007-01-15)
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter clinical trial. Preclinical studies showed antitumour activity in a broad range ...